ObjectiveThis study aimed to investigate the anti-Mycoplasma pneumoniae (MP) activity of luteolin and elucidate its underlying mechanisms. MethodsLuteolin was identified as the primary active compound from the polyphenol extract ofF. diotrys using network pharmacology. Its efficacy was evaluated against two MP strains: the standard strain M129 and the multidrug-resistant strain M19. A modified culture medium with visual characteristics was employed to determine the minimum inhibitory concentration (MIC) of luteolin. The expression of key proteins involved in MP growth and pathogenicity was assessed by qRT-PCR following luteolin treatment. Additionally, the viability of A549 cells infected with MP was compared between luteolin-treated and untreated groups. In vivo anti-MP activity was evaluated using a mouse model, and the expression of inflammatory cytokines in lung tissues was analyzed. ResultsLuteolin effectively inhibited both MP strains, with MIC₉₀ values of 100 mg/L for M19 and M129. Treatment with luteolin significantly downregulated the expression of adhesion proteins P1 and P30 in both strains. However, the expression of P65, HMW3, TrmB, and CARDS TX was reduced only in the M19 strain following luteolin intervention. Luteolin also enhanced the growth and viability of A549 cells infected with MP. In the mouse model, luteolin treatment resulted in steady weight gain and was well tolerated. The bacteriostatic rate of luteolin in lung tissues was 50.7%, significantly higher than the 25.2% observed in the roxithromycin group. Furthermore, luteolin reduced the expression of inflammatory factors, including IL-6, TNF-α, and HMGB1, in MP-infected mice. ConclusionLuteolin effectively and safely inhibits the proliferation and pathogenicity of MP, particularly the drug-resistant M19 strain, by downregulating the expression of toxicity-associated proteins (P1, P30, P65, HMW3, TrmB, CARDS TX) and modulating host inflammatory responses. These findings suggest that luteolin may offer a novel therapeutic strategy for treating MP infections, especially those caused by drug-resistant strains.

ObjectiveThis study aimed to investigate the anti-Mycoplasma pneumoniae (MP) activity of luteolin and elucidate its underlying mechanisms. MethodsLuteolin was identified as the primary active compound from the polyphenol extract ofF. diotrys using network pharmacology. Its efficacy was evaluated against two MP strains: the standard strain M129 and the multidrug-resistant strain M19. A modified culture medium with visual characteristics was employed to determine the minimum inhibitory concentration (MIC) of luteolin. The expression of key proteins involved in MP growth and pathogenicity was assessed by qRT-PCR following luteolin treatment. Additionally, the viability of A549 cells infected with MP was compared between luteolin-treated and untreated groups. In vivo anti-MP activity was evaluated using a mouse model, and the expression of inflammatory cytokines in lung tissues was analyzed. ResultsLuteolin effectively inhibited both MP strains, with MIC₉₀ values of 100 mg/L for M19 and M129. Treatment with luteolin significantly downregulated the expression of adhesion proteins P1 and P30 in both strains. However, the expression of P65, HMW3, TrmB, and CARDS TX was reduced only in the M19 strain following luteolin intervention. Luteolin also enhanced the growth and viability of A549 cells infected with MP. In the mouse model, luteolin treatment resulted in steady weight gain and was well tolerated. The bacteriostatic rate of luteolin in lung tissues was 50.7%, significantly higher than the 25.2% observed in the roxithromycin group. Furthermore, luteolin reduced the expression of inflammatory factors, including IL-6, TNF-α, and HMGB1, in MP-infected mice. ConclusionLuteolin effectively and safely inhibits the proliferation and pathogenicity of MP, particularly the drug-resistant M19 strain, by downregulating the expression of toxicity-associated proteins (P1, P30, P65, HMW3, TrmB, CARDS TX) and modulating host inflammatory responses. These findings suggest that luteolin may offer a novel therapeutic strategy for treating MP infections, especially those caused by drug-resistant strains.

Gastric cancer is a high-incidence malignancy that poses a serious threat to public health in China, ranking among the top three cancers in both incidence and mortality. The majority of patients are diagnosed at an advanced stage, resulting in limited treatment options and poor prognosis. To address key challenges in gastric cancer diagnosis and treatment, a research team led by Professor Jiafu Ji at Peking University Cancer Hospital has focused on the project "Development and Dissemination of Precision Medicine Approaches in Gastric Cancer Management". Through a series of high-quality multicenter clinical studies, the team established a set of new international standards in perioperative treatment, individua-lized drug selection, intelligent noninvasive diagnostics, and novel immunotherapy strategies. These advances have significantly improved treatment efficacy and reduced surgical trauma, achieving key technological breakthroughs in diagnosis, therapy, and mechanistic understanding, and systematically enhancing outcomes for gastric cancer patients. The project ' s findings had a broad international impact, including hosting China ' s first International Gastric Cancer Congress. Through nationwide dissemination, they have promoted the development of precision diagnosis and treatment of gastric cancer as a discipline, and led the formulation of the National Health Commission's guidelines for gastric cancer diagnosis and treatment. In recognition of its achievements, the project was awarded the First Prize of the 2024 Chinese Medical Science and Technology Award.
Stomach Neoplasms/genetics* ; Humans ; Precision Medicine/methods* ; China ; Immunotherapy/methods*

Objective To investigate the correlation between serum fibroblast growth factor 2(FGF2)and angiotensin converting enzyme 2(ACE2)levels with the severity of chronic obstructive pulmonary disease(COPD)and their predictive value for prognosis.Methods A total of 114 COPD patients treated in Hainan Cancer Hospital from June 2020 to June 2022 were selected as the study group.According to the severity of the disease,COPD patients were divided into acute exacerbation stage and stable stage.Another 114 healthy subjects were selected as control group.Serum FGF2 and ACE2 levels were detected by enzyme-linked immu-nosorbent assay.Pearson method was used to analyze the correlation between serum FGF2 and ACE2 and pul-monary function indicators.Multivariate Logistic regression was used to analyze the influencing factors of poor prognosis in COPD patients,and receiver operating characteristics(ROC)curve was plotted to analyze the predictive value of serum FGF2 and ACE2 for poor prognosis in COPD patients.Results Serum FGF2 level in the study group was significantly higher than that in the control group(P＜0.05),and serum ACE2 level,the ratio of exertional expiratory volume in the first second to predicted(FEV1％),the ratio of FEV1 to forced vi-tal capacity(FEV1/FVC),and peak expiratory flow rate(PEF)in the study group were significantly lower than those in the control group(P＜0.05).Serum FGF2 level in acute exacerbation was significantly higher than that in stable stage(P＜0.05),serum ACE2 level,FEV1％,FEV1/FVC and PEF were significantly low-er than that in stable stage(P＜0.05).Pearson correlation analysis showed that serum FGF2 and ACE2 levels were negatively correlated(P＜0.05),and serum FGF2 and ACE2 were correlated with FEV1％,FEV1/FVC and PEF(P＜0.05).The serum FGF2 level in the poor prognosis group was significantly higher than that in the good prognosis group(P＜0.05),and the serum ACE2 level was significantly lower than that in the good prognosis group(P＜0.05).Multivariate Logistic regression analysis showed that FGF2 was a risk factor for adverse prognosis in COPD patients(P＜0.05),and ACE2 was a protective factor(P＜0.05).According to ROC curve,the combination of serum FGF2 and ACE2 predicted the AUC of poor prognosis in COPD patients better than that predicted separately(Z=2.514,2.610,both P＜0.05).Conclusion Serum FGF2 level in-creased and ACE2 level decreased in COPD patients,both of which are closely related to the severity of the disease.Combined detection has certain predictive value for poor prognosis in COPD patients.

Objective:To prepare a monoclonal strain of mumps virus of genotype F，which is intended to be applied as a national standard strain，and to provide corresponding virus strain resources for the surveillance，prevention and control of mumps.Methods:The plaque purification technique was used to pick monoclonal strains on Vero/hSLAM cells. The biological characteristics and stability of the monoclonal virus strains were evaluated by observing the cytopathic effect of the monoclonal virus strains，morphological observation of virological characteristics，determination of virus titer and whole-genome sequencing，and mycoplasma detection.Results:After infection of Vero/hSLAM cells，the monoclonal strain of mumps virus constructed after plaque purification could cause cell fusion. Under the negative staining electron microscope，the virus particles were spherical，with a diameter between 100 and 200 nm，and had an obvious envelope. The virus titer of the 2 nd to 6 th generations was between 10 6 and 10 7 TCID 50/ml. Through whole-genome sequencing and phylogenetic analysis，the full length of the virus genome sequence was obtained as 15 384 bp，and it was confirmed that the monoclonal virus strain was of genotype F. The nucleotide difference rate between the 2 nd and 6 th generations was 0.013%. Conclusion:The monoclonal strain of mumps virus constructed in this experiment has typical cytopathic effects and typical morphological structures. The virus has good activity and stable genetic characteristics，and can be used as a candidate strain for application as a national standard strain. It can be used for reagent research and development，evaluation of immunization effects，and other subsequent work.

Objective To address the current issues of strong subjectivity in drug classification,vague classification standards,and complex influencing factors,this study aims to explore a scientific method for drug classification to reduce inventory costs and improve inventory effectiveness.Methods A total of 700 drugs were randomly selected from the historical data of a tertiary hospital in Beijing from 2021 to 2022 as the research subjects.The classification was conducted using the Principal Component Analysis(PCA)algorithm and the K-means clustering algorithm(K-means).Results The optimal number of classifications was determined to be 4,with a silhouette coefficient of 0.347 0.The 700 drugs were divided into four categories,with 363 in the first category,186 in the second,94 in the third,and 57 in the fourth.The drug classification method studied in this paper was simulated and applied to the drug inventory management of a certain tertiary hospital in the second quarter of 2023.The simulation results indicated that the classification method studied in this paper could reduce inventory costs and improve inventory effectiveness.Conclusion The drug classification method based on PCA algorithm and K-means clustering algorithm can provide a reliable basis for the management of drug inventory classification.

Objective To address the current issues of strong subjectivity in drug classification,vague classification standards,and complex influencing factors,this study aims to explore a scientific method for drug classification to reduce inventory costs and improve inventory effectiveness.Methods A total of 700 drugs were randomly selected from the historical data of a tertiary hospital in Beijing from 2021 to 2022 as the research subjects.The classification was conducted using the Principal Component Analysis(PCA)algorithm and the K-means clustering algorithm(K-means).Results The optimal number of classifications was determined to be 4,with a silhouette coefficient of 0.347 0.The 700 drugs were divided into four categories,with 363 in the first category,186 in the second,94 in the third,and 57 in the fourth.The drug classification method studied in this paper was simulated and applied to the drug inventory management of a certain tertiary hospital in the second quarter of 2023.The simulation results indicated that the classification method studied in this paper could reduce inventory costs and improve inventory effectiveness.Conclusion The drug classification method based on PCA algorithm and K-means clustering algorithm can provide a reliable basis for the management of drug inventory classification.

Objective:To prepare a monoclonal strain of mumps virus of genotype F，which is intended to be applied as a national standard strain，and to provide corresponding virus strain resources for the surveillance，prevention and control of mumps.Methods:The plaque purification technique was used to pick monoclonal strains on Vero/hSLAM cells. The biological characteristics and stability of the monoclonal virus strains were evaluated by observing the cytopathic effect of the monoclonal virus strains，morphological observation of virological characteristics，determination of virus titer and whole-genome sequencing，and mycoplasma detection.Results:After infection of Vero/hSLAM cells，the monoclonal strain of mumps virus constructed after plaque purification could cause cell fusion. Under the negative staining electron microscope，the virus particles were spherical，with a diameter between 100 and 200 nm，and had an obvious envelope. The virus titer of the 2 nd to 6 th generations was between 10 6 and 10 7 TCID 50/ml. Through whole-genome sequencing and phylogenetic analysis，the full length of the virus genome sequence was obtained as 15 384 bp，and it was confirmed that the monoclonal virus strain was of genotype F. The nucleotide difference rate between the 2 nd and 6 th generations was 0.013%. Conclusion:The monoclonal strain of mumps virus constructed in this experiment has typical cytopathic effects and typical morphological structures. The virus has good activity and stable genetic characteristics，and can be used as a candidate strain for application as a national standard strain. It can be used for reagent research and development，evaluation of immunization effects，and other subsequent work.

Objective To analyze the medication rules of compound patents for the prevention and treatment of viral pneumonia through data mining technology,and to provide new ideas for clinical diagnosis and treatment and new drug research and development.Methods Summarizing the patents of traditional Chinese medicine compounds for the prevention and treatment of viral pneumonia in Patent Announcement module of China National Intellectual Property Administration website,search time is from database establishment to December 31,2023,and the statistics on the frequency of use,medicinal properties,efficacy classification,association analysis,and cluster analysis were carried out with the help of data mining software such as Excel 2019,IBM SPSS Statistics 26.0,and IBM SPSS Modeler 18.0.Results Through screening,a total of 218 compound patents met the inclusion criteria,involving 424 kinds of Chinese materia medica,and the top 5 herbs with the highest frequency of use were Glycyrrhizae Radix et Rhizoma,Lonicerae Japonicae Flos,Forsythiae Fructus,Scutellariae Radix,and Platycodon Radix.The medicinal properties are bitter and cold,and mostly belong to the lung meridian.There were 4 medicinal groups of pair medicine,13 medicinal groups of triple medicine,and 1 medicinal group with four related medicine exhibiting strong correlation.A total of 6 high-frequency combinations of traditional Chinese medicine were obtained by cluster analysis.Conclusion The basic pathogenesis of viral pneumonia is that internal deficiency and evil enter,heat toxin is trapped in the ling,the phlegm and blood stasis is occurred inside,and affecting the lung's function of purging and eliminating.In clinical practice,the deficiency tonic drugs Astragali radix and Glycyrrhizae Radix et Rhizoma,are used to strengthen resistance,the heat-clearing drugs Lonicerae Japonicae Flos,Forsythiae Fructus,the phlegm antitussive and antiasthmatic drugs,Platycodon Radix,Armeniacae Semen Amarum,etc,are used to treat the symptoms,simultaneous treatment of the symptoms and root cause,prevention and treatment are organically combined.

Objective:To explored the feasibility and efficacy of a rapid ramp-up,2-week maximum regimen of venetoclax(VEN)plus low-dose cytarabine(LDAC)for treating relapsed/refractory acute myeloid leukemia(R/R AML).Methods:We retrospectively analyzed patients with venetoclax-na?ve R/R AML treated with VEN+LDAC between October 2018 and November 2023.On the first day,patients received 200 mg of VEN,and the dose was quickly increased to 400 mg for the rest of the treatment;cytarabine was administered subcutaneously at a low dose of 20 mg/m2/day.The treatment duration was 10 or 14 days,depending on the condition of bone marrow hyperplasia determined on the 8th day of treatment.No patients received venetoclax monotherapy.All patients responding to salvage therapy received VEN+LDAC until disease progression or transplantation.Results:Among the patients,the median follow-up duration was 27.5 months.No clinical mani-festations of tumor lysis syndrome(TLS)occurred during the treatment.The overall response rate(ORR)was 68.75%,including four com-plete responses(CR),one complete remission with incomplete hematologic recovery(CRi),and six partial responses(PR).The median num-ber of best treatment result cycles was one cycle.The median overall survival(OS)in the whole cohort was 5.8(0.5-47.2)months;the medi-an progression-free survival(PFS)was 22.2(7.3-42.9)months.The major adverse events were grade 3-4 hematologic adverse events and in-fections.Conclusions:The 8th-day myelosuppression-adjusted VEN+LDAC regimen is a feasible salvage option with a reasonable safety pro-file in patients with venetoclax-na?ve R/R AML.Most patients tolerated the 14-day treatment;the response was generally rapid in the re-sponding patients.